Skip to main content
. Author manuscript; available in PMC: 2011 Feb 2.
Published in final edited form as: Clin Cancer Res. 2008 Sep 1;14(17):5341–5347. doi: 10.1158/1078-0432.CCR-08-0793

Fig. 2.

Fig. 2

β2M antibody inhibited the growth of prostate cancer cell lines. A, β2M antibody significantly affected the cell proliferation of LNCaP and C4-2B prostate cancer cells, with a dose-dependent inhibition (0-20 μg/mL) after 2-d incubation determined by mitochondrial MTS assay (Promega). Purified β2M protein rescued the inhibitory effect on cell growth regulated by the β2M antibody. IgG (20 μg/mL) did not decrease the growth of LNCaP and C4-2B cells. The relative fold was assigned as 1.0 in the absence of β2M antibody treatment. **, P < 0.005, significant differences from the β2M-antibody – untreated group. Columns, mean of five replicate experiments; bars, SD. B, β2M antibody (10 μg/mL) inhibited the cell proliferation of a broad range of human prostate cancer cell lines, LNCaP, C4-2B, DU-145, PC3, and ARCaP, during 3-d treatment.The cell numbers were measured daily with a mitochondrial MTS method. The relative fold was assigned as 1.0 at day 0 for each prostate cancer cell line. **, P < 0.005, significant differences from day 0 for each cell line. Columns, mean of four or five replicate experiments; bars, SD.